HHS introduces tool to provide information on data breaches

The HHS Office for Civil Rights (OCR) has introduced a revised HIPAA Breach Reporting Tool (HBRT) that gives individuals information to improve identification of data breaches and help them understand how they are investigated and resolved.

The tool features navigation for searching information on breaches and reporting incidents. It also shows how breaches are resolved by the OCR so security measures within an organization can be improved.

“HHS heard from the public that we needed to focus more on the most recent breaches and clarify when entities have taken action to resolve the issues that might have led to their breaches,” said HHS Secretary Tom Price, MD. “To that end, we have taken steps to make this website, which features only larger breaches, a more positive, relevant source of information for concerned consumers.”

Public information covered by HIPPA reported to OCR during a breach is available through the tool, including the name of the entity, location, number of affected individuals and the date and type of breach.

“The HBRT provides health care organizations and consumers with the ability to more easily review breaches reported to OCR,” said Roger Severino, the director of OCR. “Furthermore, greater access to timely information strengthens consumer trust and transparency—qualities central to the Administration’s focus on a more innovative and effective government.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.